ARCHIVES

Biotherapeutics Reports LAK/IL-2 Toxicity Reduced With Constant Infusion Of IL-2

This article is from The Cancer Letter archive.

Vol. 13 No. 16 | April 17, 1987

Download PDF Visit The Full Archive

Related Articles

IOM Review Of Duke Genomics Trials To Focus On Validation, Scientific Criteria

October 22, 2010

ASCO/AUA Suggest 5-ARIs To Cut Prostate Cancer Risk

February 27, 2009

NCI awards $7.3 Million for Studies In Cancer communications

October 15, 1993

Immune System Booster Shown Safe For Prostate Cancer; Fewer Side Effects

August 29, 2008

In Congress: House Subcommittee Postpones FY2000 Markup; Porter Seeks 8% increase for NIH

July 23, 1999

FDA Discloses Avastin Regulatory History.

December 14, 2007